文献速递头颈部肿瘤放疗放疗物理与技术

头颈癌放疗患者味觉功能障碍的剂量依赖性研究

Dose-dependent taste dysfunction in head and neck cancer patients receiving radiotherapy.
PubMed 文献 · Radiat Oncol · 2025-12-04

该横断面研究于2023年8月23日至24日纳入444例新诊断、病理确诊且无远处转移的头颈癌放疗患者,评估急性毒性及味觉敏感度并建立NTCP模型。265例(60%)发生CTCAE≥2级味觉功能障碍,腮腺平均剂量是最强预测因子(AUC 0.72),腮腺受量24 Gy对应急性≥2级TD的50%耐受剂量。

要点

  • 60%头颈癌放疗患者发生CTCAE≥2级味觉功能障碍。
  • 腮腺平均剂量是急性味觉障碍最强预测因子(AUC 0.72)。
  • 腮腺Dmean 24 Gy对应急性≥2级味觉障碍50%概率。

核心结论

  • 较低BMI与味觉功能障碍显著相关,味觉功能障碍与生活质量显著相关。
  • 味觉功能障碍发生率与放疗剂量密切相关,降低腮腺剂量可降低风险。

研究设计与样本

  • 横断面研究,于2023年8月23日至24日开展。
  • 纳入新诊断、病理确诊、无远处转移的头颈癌患者444例。
  • 采用NCI CTCAE v5.0评估急性毒性,Subjective Total Taste Acuity(STTA)量表评估味觉敏感度,收集危及器官放疗剂量数据。
  • 采用描述性统计和多因素logistic回归建立NTCP模型。

主要发现

  • 444例参与者中265例(60%)发生CTCAE≥2级味觉功能障碍。
  • 急性味觉功能障碍与BMI显著相关(OR:0.936,P=0.029)。
  • 腮腺平均剂量(Dmean)是急性味觉功能障碍最具预测性的因素(AUC:0.72)。
  • 腮腺发生放疗期间急性≥2级味觉功能障碍的50%耐受剂量为24 Gy。
  • 腮腺Dmean预测3个月后长期味觉功能障碍10%、30%、50%概率的剂量分别为45、78、94 Gy,6个月后分别为80、97、105 Gy。

关键数值与推荐

  • 急性味觉功能障碍与BMI相关(OR:0.936,P=0.029)。
  • 腮腺Dmean预测急性味觉功能障碍AUC为0.72。
  • 腮腺对急性≥2级味觉功能障碍的50%耐受剂量为24 Gy。
  • 腮腺Dmean预测3个月长期味觉功能障碍10%、30%、50%概率分别为45、78、94 Gy。
  • 腮腺Dmean预测6个月长期味觉功能障碍10%、30%、50%概率分别为80、97、105 Gy。

临床怎么用

  • 放疗计划中应关注腮腺平均剂量,降低腮腺受量以降低味觉功能障碍风险。
  • 可参考腮腺Dmean与味觉功能障碍概率的NTCP模型预测风险。
  • 对低BMI患者应关注味觉功能障碍风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aimed to investigate the progression of taste dysfunction (TD) in patients with head and neck cancer (HNC) receiving radiotherapy (RT) and to develop a normal tissue complication probability (NTCP) model for predicting TD. METHODS: A cross-sectional study was conducted on August 23rd and 24th, 2023. Eligible participants included newly diagnosed, pathologically confirmed HNC patients without distant metastasis. Acute toxicities were assessed via the NCI CTCAE v5.0, and taste acuity was evaluated via the Subjective Total Taste Acuity (STTA) Scale. Radiation dose data for organs at risk (OARs) were collected. Descriptive statistics and multivariate logistic regression were employed to develop the NTCP models. RESULTS: Among the 444 participants, 265 (60%) experienced TD with a CTCAE grade ≥ 2. Acute TD was significantly associated with body mass index (BMI) (OR: 0.936, P = 0.029). The mean dose (Dmean) of the parotid glands was the most predictive factor (AUC: 0.72) for acute TD. The tolerance dose of 50% for the parotid glands to develop acute TD ≥ 2 during RT was 24 Gy. The Dmean of the parotid glands to the predicted 10%, 30% and 50% probabilities of long-term TD were 45, 78 and 94 Gy after 3 months and 80, 97 and 105 Gy after 6 months, respectively. CONCLUSIONS: A lower BMI was significantly associated with TD, and a significant correlation was observed between TD and quality of life (QoL). The incidence of TD is closely related to the radiation dose, and reducing the dose to the parotid glands can lower the risk.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zhang SM, Li FY, Hao MY, et al. Dose-dependent taste dysfunction in head and neck cancer patients receiving radiotherapy. Radiat Oncol. 2025. PMID: 41345943. doi:10.1186/s13014-025-02759-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。